{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.8"},{"groupId":"OG001","value":"37.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"7"}],"units":"Participants"}],"groups":[{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3 and cisplatin IV or carboplatin IV on day 1 (Cohort 1). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nCarboplatin: Given IV\n\nCisplatin: Given IV\n\nDocetaxel: Given IV\n\nEtoposide: Given IV\n\nPembrolizumab: Given IV","id":"OG000","title":"Cohort 1: Metastatic or Locally Advanced Naive Small Cell Bladder Cancer"},{"description":"Participants receive pembrolizumab IV over 30 minutes on day 1. Courses repeat every 3 weeks for 2 years in the absence of disease progression or unacceptable toxicity. Participants also receive standard of care chemotherapy comprising etoposide IV on days 1-3, carboplatin IV on day 1, and docetaxel IV on day 1 (Cohort 2). Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Cohort 2: Small Cell or Neuroendocrine Prostate Cancer"}],"paramType":"NUMBER","populationDescription":"PD-L1% (defined CPS\\>10). combined positive score (CPS). CPS defined as number of PD-L1 staining cells in tumor, lymphocytes, and macrophages divided by total number viable tumor cells x 100.","reportingStatus":"POSTED","timeFrame":"at 12 months","title":"Percentage of Participants With Programmed Death-ligand 1 (PD-L1) Combined Positive Score (CPS) Greater Than 10, at 12 Months","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"Percentage of patients with (CPS) > 10"}